MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Spark Therapeutics Company Profile (NASDAQ:ONCE)

Consensus Ratings for Spark Therapeutics (NASDAQ:ONCE) (?)
Ratings Breakdown: 1 Sell Rating(s), 4 Hold Rating(s), 6 Buy Rating(s)
Consensus Rating:Hold (Score: 2.45)
Consensus Price Target: $60.75 (35.36% upside)

Analysts' Ratings History for Spark Therapeutics (NASDAQ:ONCE)
Show:
DateFirmActionRatingPrice TargetActions
6/23/2016Cantor FitzgeraldReiterated RatingBuy$100.00 -> $94.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/21/2016SunTrustBoost Price TargetBuy$64.00 -> $72.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/12/2016Jefferies GroupReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/13/2016WedbushReiterated RatingUnderperform$29.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/19/2016Cowen and CompanyReiterated RatingBuy$75.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/15/2016Chardan CapitalReiterated RatingNeutral$45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/12/2016Evercore ISIInitiated CoverageBuy$37.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/30/2016Goldman SachsInitiated CoverageBuy -> Neutral$44.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/12/2016JPMorgan Chase & Co.Reiterated RatingOverweightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/24/2015WunderlichDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/11/2015Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2015Credit SuisseInitiated CoverageOutperform$76.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2015Sanford C. BernsteinInitiated CoverageMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2015Rodman & RenshawInitiated CoverageBuy$71.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/26/2014 forward)
Earnings History for Spark Therapeutics (NASDAQ:ONCE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/4/2016Q116($0.84)($0.95)$1.48 million$1.29 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/9/2016Q415($0.73)($0.24)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2015Q315($0.48)($0.70)$4.43 million$1.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215($0.13)($0.60)$4.50 million$1.29 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2015Q115($0.61)($0.58)$1.20 million$1.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Spark Therapeutics (NASDAQ:ONCE)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($1.04)($0.80)($0.88)
Q2 20164($1.00)($0.83)($0.89)
Q3 20164($1.05)($0.88)($0.95)
Q4 20164($1.09)($0.90)($0.99)
Q1 20171($1.08)($1.08)($1.08)
Q2 20171($1.08)($1.08)($1.08)
Q3 20171($1.06)($1.06)($1.06)
Q4 20171($1.01)($1.01)($1.01)
(Data provided by Zacks Investment Research)
Dividend History for Spark Therapeutics (NASDAQ:ONCE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Spark Therapeutics (NASDAQ:ONCE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/20/2016Hospital Of Philade Children'sMajor ShareholderSell1,000,000$42.30$42,300,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2016Jeffrey D MarrazzoCEOSell5,000$46.49$232,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/31/2016Anand MehraDirectorSell500$60.00$30,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2016Katherine A HighInsiderSell10,000$54.42$544,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2016Barge Joseph LaInsiderSell10,000$47.65$476,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2016Stephen W WebsterCFOSell20,000$50.39$1,007,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2016Jeffrey D MarrazzoCEOSell25,000$46.01$1,150,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/21/2016Coelho Rogerio VivaldiInsiderSell7,000$40.02$280,140.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/28/2015Hospital Of Philade Children'sMajor ShareholderSell131,505$44.18$5,809,890.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/21/2015Hospital Of Philade Children'sMajor ShareholderSell1,000,000$44.18$44,180,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2015Katherine A HighInsiderSell10,000$55.31$553,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/27/2015Anand MehraDirectorSell22,961$60.01$1,377,889.61View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/16/2015Katherine A HighInsiderSell10,000$53.77$537,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2015Anand MehraDirectorSell130,605$60.11$7,850,666.55View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/14/2015Katherine A. HighinsiderSell30,000$49.34$1,480,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/13/2015Katherine A. HighinsiderSell10,000$48.00$480,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/12/2015Jeffrey D. MarrazzoCEOSell75,000$48.35$3,626,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/9/2015Jeffrey D. MarrazzoCEOSell75,000$47.82$3,586,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/8/2015Anand MehraDirectorSell529,544$45.46$24,073,070.24View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2015Coelho Rogerio VivaldiinsiderSell41,000$48.85$2,002,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2015Stephen W. WebsterCFOSell20,000$48.86$977,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2015Steven AltschulerDirectorBuy5,000$49.11$245,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/4/2015Anand MehraDirectorBuy225,000$23.00$5,175,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/4/2015Hospital Of Philade Children'sMajor ShareholderBuy100,000$23.00$2,300,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/4/2015Stephen W WebsterCFOBuy2,500$23.00$57,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Spark Therapeutics (NASDAQ:ONCE)
DateHeadline
06/26/16 10:11 AMCantor Fitzgerald disclosed (NASDAQ:ONCE) Spark Therapeutics, dropping its target price to $94 today - Breaking Finance News
06/25/16 09:23 AMCantor Fitzgerald disclosed (NASDAQ:ONCE) Spark Therapeutics, dropping its target price to $94 today
06/23/16 08:19 AMSpark Therapeutics Incorporated (NASDAQ:ONCE) Short Interest Increased By 34.56% - Press Telegraph
06/22/16 05:33 PMSuntrust Robinson announced (NASDAQ:ONCE) Spark Therapeutics, raising its price target to $72 earlier today
06/21/16 05:13 PMSpark Therapeutics Announces Closing of Public Offering - GlobeNewswire (press release)
06/20/16 05:27 PMStrong Buy Calls Count For Spark Therapeutics, Inc. (NASDAQ:ONCE) At 4 - Investor Newswire
06/20/16 03:19 PMSpark Therapeutics Announces Closing of Public Offering - [at noodls] - PHILADELPHIA, June 20, 2016 (GLOBE NEWSWIRE) -- Spark Therapeutics, Inc. ('Spark') (NASDAQ:ONCE) announced today the closing of its previously announced underwritten public offering of common stock pursuant ...
06/16/16 05:52 PMEye Catching Stock: Spark Therapeutics, Inc. (NASDAQ:ONCE) - News Oracle
06/16/16 09:51 AMHC Stocks Highlights: Eli Lilly and Co (NYSE:LLY), Spark Therapeutics Inc (NASDAQ:ONCE) - share market updates (press release)
06/16/16 09:51 AMSummary of Analyst's Study: Pfizer, Inc. (NYSE:PFE) , Spark Therapeutics, Inc. (NASDAQ:ONCE) - Street Updates
06/16/16 09:51 AMSpark Therapeutics (ONCE) Stock: Weak On High Volume Today - TheStreet.com
06/16/16 07:54 AM5 things to know & more reasons to stay & dine in Old City -
06/15/16 05:37 PMStocks Showing Momentum: Telefonica (NYSE:TEF), Spark Therapeutics (NASDAQ:ONCE) - Beacon Chronicle
06/15/16 05:37 PMSpark Therapeutics (ONCE) Prices 3.5M Common Stock Offering at $45/Share - StreetInsider.com
06/15/16 03:47 PMSPARK THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Stat -
06/15/16 11:35 AMStock sale to net $106M for Spark Therapeutics, $42M for CHOP -
06/15/16 10:14 AMSouthwest Airlines Co. (NYSE:LUV) plummeted -5.41%: Spark Therapeutics, Inc. (NASDAQ:ONCE), Benefitfocus, Inc ... - KC Register
06/15/16 10:14 AMTrading updates about two Stocks: Spark Therapeutics, Inc. (NASDAQ:ONCE) , Regeneron Pharmaceuticals, Inc ... - Street Updates
06/15/16 10:14 AMSpark Therapeutics (ONCE) Trading With Heavy Volume Before Market Open - TheStreet.com
06/15/16 10:14 AMSpark Therapeutics Announces Pricing of Public Offering - GlobeNewswire (press release)
06/13/16 05:11 PMSpark Therapeutics (ONCE) Commences 3.5M Share Stock Offering
06/13/16 04:09 PMSpark Therapeutics Announces Launch of Public Offering - [at noodls] - PHILADELPHIA, June 13, 2016 (GLOBE NEWSWIRE) -- Spark Therapeutics, Inc. ('Spark') (NASDAQ:ONCE) announced today that it has commenced an underwritten public offering of 3,500,000 shares of its common ...
06/13/16 08:34 AMSpark Therapeutics (ONCE) Offers Updated Data from First Cohort of SPK-9001 Phase 1/2 in Hemophilia B - StreetInsider.com
06/13/16 07:30 AMSpark Therapeutics Inc Conference Call to Discuss Results from Ongoing Phase 1/2 Clinical Trial of SPK-9001 scheduled for 8:30 am ET today -
06/13/16 06:39 AMSpark Therapeutics Announces Updated Data from First Cohort in Hemophilia B Phase 1/2 Trial Demonstrating Consistent, Sustained Therapeutic Levels of Factor IX Activity - [at noodls] - All four subjects received one-time administration of SPK-9001 at initial low dose for a cumulative 58-weeks of follow-up without the need for immunosuppression Lead investigational candidate, SPK-8011, ...
06/09/16 06:00 PMJefferies Initiates Coverage on Spark Therapeutics Inc to Hold - Trade Calls
06/09/16 08:35 AMCantor Fitzgerald Initiates Coverage on Spark Therapeutics Inc to Buy - Trade Calls
06/09/16 06:39 AMSpark Therapeutics, Inc. to Host Conference Call on Monday June 13th at 8:30 a.m. to Discuss SPK-9001 Phase 1/2 Data for the Treatment of Hemophilia B Presented at EHA - [at noodls] - PHILADELPHIA, June 09, 2016 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE) announced today that it will host a conference call on Monday, June 13, 2016 at 8:30 a.m. ET to discuss updated results ...
06/09/16 06:32 AM7:32 am Spark Therapeutics to host conference call on Monday June 13 at 8:30am to discuss SPK-9001 Phase 1/2 data for the treatment of hemophilia B presented at EHA -
06/08/16 06:01 PMSPARK THERAPEUTICS INC. (NASDAQ:ONCE) Financial Condition Compared to S&P 500 - CML News
06/08/16 08:40 AMTwo Buzzers within Investors Radar: Argos Therapeutics, Inc. (NASDAQ:ARGS) , Spark Therapeutics, Inc. (NASDAQ ... - Street Updates
06/06/16 05:34 PMSpark Therapeutics Announces Participation and Attendance for Conferences in June - GlobeNewswire (press release)
06/06/16 05:34 PMAnalysts and Technical Report on Spark Therapeutics Inc (NASDAQ:ONCE) - Street Report
06/06/16 09:21 AMSpark Therapeutics, Inc. (NASDAQ:ONCE) Broker Price Targets For The Coming Week - Share Trading News
06/06/16 09:21 AMStock Review and Earnings Check on Spark Therapeutics, Inc. (NASDAQ:ONCE) - HNN
06/06/16 09:21 AMSpark Therapeutics Inc Expected to Earn Q2 2016 Earnings of ($1.00) Per Share (ONCE) - Let Me Know About This
06/06/16 06:48 AMSpark Therapeutics Announces Participation and Attendance for Conferences in June - [at noodls] - PHILADELPHIA, June 06, 2016 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE) announced today that members of its management team will participate in and attend the following conferences in June: Presenting ...
06/05/16 05:40 PMPerformance Review for Spark Therapeutics, Inc. (NASDAQ:ONCE) - HNN
06/05/16 08:20 AMSpark Therapeutics Inc (ONCE) Stock Rating Reaffirmed by Cowen and Company - Let Me Know About This
06/03/16 06:08 PMSpark Therapeutics Inc 72.8% Potential Upside Now Implied by Cantor Fitzgerald - DirectorsTalk Interviews
06/03/16 03:04 PMSPARK THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/03/16 08:31 AMShare Rating Focus on Spark Therapeutics, Inc. (NASDAQ:ONCE) - HNN - Share Rating Focus on Spark Therapeutics, Inc. (NASDAQ:ONCE)HNNThis stock research may entail following what professional equity analysts think about the company. Presently, Wall Street analysts have given a consensus stock rating of 2.2 on shares of Spark Therapeutics, Inc. (NASDAQ:ONCE). Covering analysts will ...and more »
06/03/16 08:31 AMSpark Therapeutics Inc (ONCE) Now Covered by Analysts at Cantor Fitzgerald - Let Me Know About This - BenzingaSpark Therapeutics Inc (ONCE) Now Covered by Analysts at Cantor FitzgeraldLet Me Know About ThisSpark Therapeutics logo Equities research analysts at Cantor Fitzgerald initiated coverage on shares of Spark Therapeutics Inc (NASDAQ:ONCE) in a note issued to investors on Thursday. The brokerage set a “buy” rating and a $100.00 price target on the ...Spark Therapeutics Inc (ONCE) is Initiated by Cantor Fitzgerald to Buy, Price Target at $100Market DigestCantor Fitzgerald Begins Coverage on Spark Therapeutics Inc (ONCE)Community Financial NewsJefferies Group Initiates Coverage on Spark Therapeutics Inc (ONCE)The Cerbat GemThe Post -Benzinga -Share Trading Newsall 25 news articles »
06/02/16 06:01 PMTarget Price and Stock Performance Rundown for Spark Therapeutics, Inc. (NASDAQ:ONCE) - HNN - Target Price and Stock Performance Rundown for Spark Therapeutics, Inc. (NASDAQ:ONCE)HNNKeeping an eye on share activity using multiple views may be helpful when tracking stock performance. Equity investors have the ability to track short or long term share performance. During the latest trading session, Spark Therapeutics, Inc. (NASDAQ ...and more »
06/02/16 06:01 PMSpark Therapeutics, Inc. (NASDAQ:ONCE) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News - Spark Therapeutics, Inc. (NASDAQ:ONCE) Do Brokers Advise Buy, Sell Or Hold?Share Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Spark Therapeutics, Inc. (NASDAQ:ONCE). The latest reports which are currently in issue on Thursday 2nd of June state 0 analysts have a rating of “strong buy”, 0 ...and more »
06/02/16 05:32 AMCoverage initiated on Spark Therapeutics by Jefferies -
06/01/16 08:33 AMSpark Therapeutics, Inc. (NASDAQ:ONCE) Stock Update & Estimates - Stock Tick Tock - Spark Therapeutics, Inc. (NASDAQ:ONCE) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting Spark Therapeutics, Inc. (NASDAQ:ONCE) to post earnings of $-0.98 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be ...and more »
05/27/16 03:42 PMHelping the blind to see -
05/27/16 11:53 AMStock Rating Review for Spark Therapeutics, Inc. (NASDAQ:ONCE) - Wall Street Hints and News - Stock Rating Review for Spark Therapeutics, Inc. (NASDAQ:ONCE)Wall Street Hints and NewsInvestors may choose to follow the views of professional Wall Street analysts that regularly track the company. Covering equity analysts presently have a consensus stock rating of 2.2 on shares of Spark Therapeutics, Inc. (NASDAQ:ONCE). Covering ...and more »
05/26/16 10:59 AMTarget Check and Stock Performance Recap Spark Therapeutics, Inc. (NASDAQ:ONCE) - Wall Street Hints and News - Target Check and Stock Performance Recap Spark Therapeutics, Inc. (NASDAQ:ONCE)Wall Street Hints and NewsTracking stock performance from various views may help with share evaluation. Some investors might be more focused on short-term share action while others may prefer to view long-term performance. In recent session activity, Spark Therapeutics, Inc.and more »
About Spark Therapeutics

Spark Therapeutics logoSpark Therapeutics, Inc. (Spark) is engaged in developing products in the field of gene therapy. Spark's product candidate, SPK-RPE65, which is in Phase III clinical trial stage, targets a group of rare blinding conditions known as inherited retinal dystrophies (IRDs), caused by non-sex linked or autosomal recessive mutations in the RPE65 gene. Spark is also developing various follow-on product candidates targeting other IRDs, including SPK-CHM for the treatment of choroideremia (CHM). SPK-CHM is in Phase I/II dose-escalating clinical trial stage. The Company's product development portfolio includes product candidates targeting expression of genes in the liver, with a focus on hematologic disorders. The Company is also engaged in the development and commercialization of product candidates in its SPK-FIX program for the treatment of hemophilia B. Spark also has preclinical programs in development for the treatment of hemophilia A and neurodegenerative diseases.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ONCE
  • CUSIP:
Key Metrics:
  • Previous Close: $44.88
  • 50 Day Moving Average: $47.37
  • 200 Day Moving Average: $38.10
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $1.23B
  • Current Quarter EPS Consensus Estimate: $-3.92 EPS
Additional Links:
Spark Therapeutics (NASDAQ:ONCE) Chart for Sunday, June, 26, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha